IGIC vs IVA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGIC is a StrongBuy and IVA is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IGIC’s FA Score shows that 2 FA rating(s) are green whileIVA’s FA Score has 0 green FA rating(s).
- IGIC’s FA Score: 2 green, 3 red.
- IVA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IGIC’s TA Score shows that 5 TA indicator(s) are bullish while IVA’s TA Score has 4 bullish TA indicator(s).
- IGIC’s TA Score: 5 bullish, 4 bearish.
- IVA’s TA Score: 4 bullish, 3 bearish.
Price Growth
IGIC (@Multi-Line Insurance) experienced а -1.33% price change this week, while IVA (@Biotechnology) price change was +12.58% for the same time period.
The average weekly price growth across all stocks in the @Multi-Line Insurance industry was +1.62%. For the same industry, the average monthly price growth was +0.96%, and the average quarterly price growth was +10.86%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.67%. For the same industry, the average monthly price growth was -9.26%, and the average quarterly price growth was -12.98%.
Reported Earning Dates
IGIC is expected to report earnings on Aug 14, 2025.
IVA is expected to report earnings on Sep 25, 2025.
Industries' Descriptions
@Multi-Line Insurance (+1.62% weekly)A multi-line insurance contract bundles together exposures to risk and covers them under a single contract. For providers of such policies, the bundle is a potential risk diversification strategy since their exposure gets spread over several factors, which helps them mitigate a financial burden if a catastrophic event were to occur. Other potential benefits include getting more premiums from including more than one type of insurance in a bundle, and getting a competitive edge by procuring multiple insurance contracts with a customer. Examples of companies in this industry are Berkshire Hathaway (which owns several insurance companies), Chubb Limited, American International Group, Inc. and Sun Life Financial Inc.
@Biotechnology (+7.67% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| IGIC | IVA | IGIC / IVA | |
| Capitalization | 612M | 310M | 197% |
| EBITDA | N/A | N/A | - |
| Gain YTD | 6.485 | 78.972 | 8% |
| P/E Ratio | 6.12 | N/A | - |
| Revenue | 491M | N/A | - |
| Total Cash | N/A | N/A | - |
| Total Debt | 3.07M | N/A | - |
IGIC | ||
|---|---|---|
OUTLOOK RATING 1..100 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | |
SMR RATING 1..100 | 42 | |
PRICE GROWTH RATING 1..100 | 40 | |
P/E GROWTH RATING 1..100 | 12 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IGIC | IVA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 69% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 70% |
| Advances ODDS (%) | 9 days ago 65% | 2 days ago 74% |
| Declines ODDS (%) | 17 days ago 45% | N/A |
| BollingerBands ODDS (%) | 2 days ago 81% | 2 days ago 79% |
| Aroon ODDS (%) | N/A | 2 days ago 78% |
IGIC and
Correlation & Price change
A.I.dvisor indicates that over the last year, IGIC has been loosely correlated with ORI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IGIC jumps, then ORI could also see price increases.
| Ticker / NAME | Correlation To IGIC | 1D Price Change % | ||
|---|---|---|---|---|
| IGIC | 100% | +2.47% | ||
| ORI - IGIC | 48% Loosely correlated | +3.49% | ||
| FIHL - IGIC | 40% Loosely correlated | +3.72% | ||
| AIG - IGIC | 38% Loosely correlated | +2.85% | ||
| EQH - IGIC | 37% Loosely correlated | +4.36% | ||
| SLF - IGIC | 30% Poorly correlated | +1.15% | ||
More | ||||